Specific effects on the thyroid relevant for performing a dietary cumulative risk assessment of pesticide residues: 2024 update

• Published in: EFSA journal Vol. 22; no. 3; pp. e8672 - n/a
• Main Authors: Crivellente, Federica, Hernández‐Jerez, Antonio F., Lanzoni, Anna, Metruccio, Francesca, Mohimont, Luc, Nikolopoulou, Dimitra, Castoldi, Anna F.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.03.2024; John Wiley and Sons Inc; Wiley
• Subjects: cumulative risk assessment; cumulative toxicity; Data collection; endocrine; Histopathology; Hyperplasia; Hypertrophy; Hypothyroidism; Indicators; Metabolites; Pesticide residues; Pesticides; Plant protection; Probability; Regulation; Residues; Risk assessment; Scientific Report; Thyroid; Thyroid gland; Trinucleotide repeats; Tumors; cumulative toxicity; pesticide residues; thyroid; hypothyroidism; cumulative risk assessment; endocrine
• ISSN: 1831-4732; 1831-4732; 2314-9396
• DOI: 10.2903/j.efsa.2024.8672

EFSA updated its previous work on the establishment of specific effects that are considered relevant for grouping pesticide residues targeting the thyroid and for performing the retrospective assessment of dietary cumulative risk (CRA). The two specific effects already selected in 2019 leading to the two cumulative assessment groups (CAGs) ‘hypothyroidism’ and ‘C‐cell hypertrophy, hyperplasia and neoplasia’ were reconfirmed. Compared to 2019, the list of indicators that can be used to identify these specific effects was refined to only include histopathological changes. In a second phase of the work, data will be extracted on indicators of the specific effects from the dossiers on active substances (a.s.) used as plant protection products. The criteria for including a.s. into CAGs were also updated, together with the hazard characterisation methodology and the lines of evidence for assessing CAG‐membership probabilities. The tasks related to the data extraction and the establishment of the CAGs on hypothyroidism and on C‐cell hypertrophy, hyperplasia and neoplasia are beyond the scope of this report. This part of the CRA process has been outsourced and will be the subject of a separate report.